STRATA Skin Sciences Earnings Call Transcripts
Fiscal Year 2025
-
Q3 2025 saw strong U.S. recurring revenue and record device billings, offset by a 20% drop in total revenue due to international headwinds. Expanded CPT codes and litigation wins are set to drive future growth, with TheraClearX expanding in Mexico and the U.S.
-
Q2 2025 revenue declined 9% year-over-year to $7.7M, mainly due to international headwinds, but expanded CPT codes and new clinical evidence position the business for significant growth in 2026. Litigation against LaserOptec progressed, and CMS decisions on reimbursement are pending.
-
Q1 2025 saw continued growth in recurring revenue per device, margin expansion, and improved cash flow, driven by strategic initiatives like Elevate 360 and TheraClearX deployment. International revenue rose 8%, but future results may be impacted by tariffs.
Fiscal Year 2024
-
Q4 2024 saw 10% revenue growth, record international sales, and improved gross margin to 60%. Device utilization and average revenue per device rose, while operating loss narrowed significantly. Strong cash position and strategic execution support a positive 2025 outlook.
-
Q3 2024 results show stabilization, with revenue per XTRAC device up 2% year-over-year and gross margin improving to 60.3%. DTC initiatives and TheraClear X adoption drove growth, while a $1.8M one-time accrual impacted operating expenses.
-
A virtual healthcare conference session highlighted a dermatology device company’s recurring revenue model, strong clinical support, and expanding device base. Leadership emphasized high margins, exclusive market position, and a focus on self-funded growth with potential for M&A or strategic exit.
-
A unique device placement and service model is driving recurring revenue growth, margin expansion, and a turnaround, with strong clinical backing and significant domestic and international expansion opportunities. M&A and operational improvements are central to future plans.
-
Q2 2024 revenue grew 2% year-over-year to $8.4 million, with gross margin improving to 58.5%. Operating expenses fell 14%, and a $2.1 million capital raise post-quarter supports ongoing turnaround efforts. DTC marketing expansion and device optimization are driving operational improvements.